Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04128683 · ClinicalTrials.gov registry record · Early Phase 1
Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
A Early Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
NCT04128683 is a Early Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 31 participants.
The verdict
NCT04128683, a Early Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Anorexia nervosa (AN) is an eating disorder associated with intense fear of weight gain, food refusal, and severe weight loss. AN has the highest mortality rate among the psychiatric disorders; however, little is known about biomarkers, and no medication has been approved for AN. Many individuals only partially recover, and treatment options, especially for the psychological components of the illness, are not very effective, highlighting the need for more effective treatments. Brain reward pathways have a direct impact on the drive to eat, and a variety of neuroimaging studies have suggested altered reward processing in AN. The neurotransmitter dopamine has a central role in the reward circuitry to drive food approach, and the dynamic interplay between dopamine receptor response and food restriction could have implications for the pathophysiology of AN. Dopamine-related brain function has been studied indirectly using functional magnetic resonance brain imaging (fMRI) and tasks that deliver reward stimuli unexpectedly, that elicit the so-called prediction error (PE) response. Research in AN showed repeatedly altered PE processing suggesting altered dopamine circuit function in the disorder. Dopamine and PE response have also been associated with altered reversal learning, which has important treatment implication for AN as reversal learning is impaired in the disorder and modulation of the dopamine system could improve treatment.
Interventions
- DRUG Placebo
- DRUG amisulpride
- DRUG bromocriptine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2025-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04128683
The ClinicalTrials.gov registry entry for NCT04128683 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04128683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04128683 about?
NCT04128683 is a clinical study titled "Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa". Anorexia nervosa (AN) is an eating disorder associated with intense fear of weight gain, food refusal, and severe weight loss. AN has the highest mortality rate among the psychiatric disorders; however, little is known about biomarkers, and no medication has been approved for AN. Many individuals on...
What is the current status of trial NCT04128683?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2020-10-20. Estimated completion is 2025-01-01.
What interventions are being tested in trial NCT04128683?
The interventions under investigation include: Placebo (DRUG), amisulpride (DRUG), bromocriptine (DRUG).
Who is sponsoring clinical trial NCT04128683?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.